CAMP4 THERAPEUTICS CORP (CAMP) Fundamental Analysis & Valuation
NASDAQ:CAMP • US13463J1016
Current stock price
4.44 USD
0 (0%)
At close:
4.44 USD
0 (0%)
After Hours:
This CAMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CAMP Profitability Analysis
1.1 Basic Checks
- In the past year CAMP has reported negative net income.
- CAMP had a negative operating cash flow in the past year.
- In the past 5 years CAMP always reported negative net income.
- CAMP had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -67.80%, CAMP is doing worse than 64.53% of the companies in the same industry.
- With a Return On Equity value of -166.67%, CAMP is not doing good in the industry: 66.86% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.8% | ||
| ROE | -166.67% | ||
| ROIC | N/A |
ROA(3y)-74.52%
ROA(5y)-55.93%
ROE(3y)-126.05%
ROE(5y)-97.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CAMP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CAMP Health Analysis
2.1 Basic Checks
- CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CAMP has more shares outstanding
- Compared to 5 years ago, CAMP has more shares outstanding
- CAMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CAMP has an Altman-Z score of -1.93. This is a bad value and indicates that CAMP is not financially healthy and even has some risk of bankruptcy.
- CAMP has a Altman-Z score of -1.93. This is comparable to the rest of the industry: CAMP outperforms 49.42% of its industry peers.
- CAMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.93 |
ROIC/WACCN/A
WACC9.59%
2.3 Liquidity
- A Current Ratio of 7.13 indicates that CAMP has no problem at all paying its short term obligations.
- With a decent Current ratio value of 7.13, CAMP is doing good in the industry, outperforming 67.25% of the companies in the same industry.
- A Quick Ratio of 7.13 indicates that CAMP has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 7.13, CAMP is in the better half of the industry, outperforming 67.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 7.13 |
3. CAMP Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 90.19% over the past year.
- The Revenue for CAMP has decreased by -95.11% in the past year. This is quite bad
- CAMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.51% yearly.
EPS 1Y (TTM)90.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.61%
Revenue 1Y (TTM)-95.11%
Revenue growth 3YN/A
Revenue growth 5Y-59.51%
Sales Q2Q%-46.63%
3.2 Future
- The Earnings Per Share is expected to grow by 12.78% on average over the next years. This is quite good.
- The Revenue is expected to grow by 86.07% on average over the next years. This is a very strong growth
EPS Next Y69.98%
EPS Next 2Y30.06%
EPS Next 3Y20.26%
EPS Next 5Y12.78%
Revenue Next Year-28.15%
Revenue Next 2Y1.36%
Revenue Next 3Y50.4%
Revenue Next 5Y86.07%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. CAMP Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CAMP. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAMP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CAMP's earnings are expected to grow with 20.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.06%
EPS Next 3Y20.26%
5. CAMP Dividend Analysis
5.1 Amount
- No dividends for CAMP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CAMP Fundamentals: All Metrics, Ratios and Statistics
4.44
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2026-03-05/amc
Earnings (Next)05-11 2026-05-11
Inst Owners79.53%
Inst Owner Change0%
Ins Owners1.32%
Ins Owner Change0%
Market Cap230.52M
Revenue(TTM)3.50M
Net Income(TTM)-80.00M
Analysts85
Price Target8.93 (101.13%)
Short Float %0.95%
Short Ratio1.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-95.34%
Min EPS beat(2)-177.96%
Max EPS beat(2)-12.73%
EPS beat(4)2
Avg EPS beat(4)-41.99%
Min EPS beat(4)-177.96%
Max EPS beat(4)13.17%
EPS beat(8)2
Avg EPS beat(8)-340.59%
EPS beat(12)4
Avg EPS beat(12)-228.37%
EPS beat(16)7
Avg EPS beat(16)-175.52%
Revenue beat(2)1
Avg Revenue beat(2)11.76%
Min Revenue beat(2)-26.36%
Max Revenue beat(2)49.89%
Revenue beat(4)3
Avg Revenue beat(4)858.21%
Min Revenue beat(4)-26.36%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)456.44%
Revenue beat(12)6
Avg Revenue beat(12)303.88%
Revenue beat(16)6
Avg Revenue beat(16)226.5%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.25%
EPS NY rev (1m)15.52%
EPS NY rev (3m)15.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)195.83%
Revenue NY rev (1m)-19.99%
Revenue NY rev (3m)4.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 65.86 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.8 | ||
| P/tB | 4.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.65
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.07
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.8% | ||
| ROE | -166.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-74.52%
ROA(5y)-55.93%
ROE(3y)-126.05%
ROE(5y)-97.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 17.07% | ||
| Cap/Sales | 8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | -1.93 |
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)27.81%
Cap/Depr(5y)118.7%
Cap/Sales(3y)89.92%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.61%
EPS Next Y69.98%
EPS Next 2Y30.06%
EPS Next 3Y20.26%
EPS Next 5Y12.78%
Revenue 1Y (TTM)-95.11%
Revenue growth 3YN/A
Revenue growth 5Y-59.51%
Sales Q2Q%-46.63%
Revenue Next Year-28.15%
Revenue Next 2Y1.36%
Revenue Next 3Y50.4%
Revenue Next 5Y86.07%
EBIT growth 1Y6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.13%
EBIT Next 3Y-15.61%
EBIT Next 5YN/A
FCF growth 1Y34.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.78%
OCF growth 3YN/A
OCF growth 5YN/A
CAMP4 THERAPEUTICS CORP / CAMP Fundamental Analysis FAQ
What is the fundamental rating for CAMP stock?
ChartMill assigns a fundamental rating of 3 / 10 to CAMP.
What is the valuation status of CAMP4 THERAPEUTICS CORP (CAMP) stock?
ChartMill assigns a valuation rating of 1 / 10 to CAMP4 THERAPEUTICS CORP (CAMP). This can be considered as Overvalued.
What is the profitability of CAMP stock?
CAMP4 THERAPEUTICS CORP (CAMP) has a profitability rating of 0 / 10.
How financially healthy is CAMP4 THERAPEUTICS CORP?
The financial health rating of CAMP4 THERAPEUTICS CORP (CAMP) is 7 / 10.
Can you provide the expected EPS growth for CAMP stock?
The Earnings per Share (EPS) of CAMP4 THERAPEUTICS CORP (CAMP) is expected to grow by 69.98% in the next year.